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Abstract
Background
Unprovoked venous thromboembolism (VTE) is related to a higher incidence of occult can-
cer. D-dimer is clinically used for screening VTE, and has often been shown to be present in
patients with malignancy. We explored the predictive value of D-dimer for detecting occult
cancer in patients with unprovoked VTE.
Methods
We retrospectively examined data from 824 patients diagnosed with deep vein thrombosis or
pulmonary thromboembolism. Of these, 169 (20.5%) patients diagnosed with unprovoked
VTE were selected to participate in this study. D-dimer was categorized into three groups as:
<2,000, 2,000–4,000, and >4,000 ng/ml. Cox regression analysis was employed to estimate
the odds of occult cancer and metastatic state of cancer according to D-dimer categories.
Results
During a median 5.3 (interquartile range: 3.4–6.7) years of follow-up, 24 (14%) patients with
unprovoked VTE were diagnosed with cancer. Of these patients, 16 (67%) were identified
as having been diagnosed with metastatic cancer. Log transformed D-dimer levels were
significantly higher in those with occult cancer as compared with patients without diagnosis
of occult cancer (3.5±0.5 vs. 3.2±0.5, P-value = 0.009, respectively). D-dimer levels >4,000
ng/ml was independently associated with occult cancer (HR: 4.12, 95% CI: 1.54–11.04, P-
value = 0.005) when compared with D-dimer levels <2,000 ng/ml, even after adjusting for
age, gender, and type of VTE (e.g., deep vein thrombosis or pulmonary thromboembolism).
D-dimer levels >4000 ng/ml were also associated with a higher likelihood of metastatic can-
cer (HR: 9.55, 95% CI: 2.46–37.17, P-value <0.001).
Conclusion
Elevated D-dimer concentrations >4000 ng/ml are independently associated with the likeli-
hood of occult cancer among patients with unprovoked VTE.
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Introduction
Venous thromboembolism (VTE) that includes deep vein thrombosis (DVT) and pulmonary
embolism (PE) is closely linked with a higher burden of cancer. Foremost, cancer is known to
provoke the onset of VTE, and reciprocally, VTE along with its complications are frequently
involved in the poor prognosis observed among patients with cancer. Previous studies reported
that up to 30% of all first VTE occurred in patients with cancer [1,2]. Provoked VTE is typically
defined as VTE occurring in the presence of a risk factor such as a recognizable cancer, preg-
nancy, or major surgery. Conversely, unprovoked VTE is considered to occur in the absence of
any discernable risk factors [3]. To this end, unprovoked VTE is considered the first manifesta-
tion in patients with occult cancer. Further still, prior studies have documented that the risk of
cancer appeared to increase in patients presenting with unprovoked VTE, particularly during
an early follow-up period [4–6].
D-dimer represents a biomarker that reflects the activation of hemostasis and fibrinolysis.
In recent past, D-dimer has displayed high sensitivity for diagnosis of VTE and its related adverse
outcomes [7–9]. Current guidelines recommend the use of measuring D-dimer in patients for
the purpose of screening for suspected VTE [3]. Further still, elevated D-dimer levels have been
shown to be present in those with malignancies, with the relationship between high D-dimer
concentrations and the presence of cancer reported elsewhere [10–12]. While it appears eleva-
tions in D-dimer levels are independently linked with VTE as well as cancer, to date, the predic-
tive value of D-dimer and its relationship with occult cancer in patients with VTE remains to be
firmly established. We therefore aimed to evaluate whether D-dimer might serve as a useful tool
for predicting occult cancer in patients who present with unprovoked VTE.
Materials and Methods
Study design and population
We retrospectively reviewed medical records of patients who were diagnosed with DVT or PE
from January 2007 to October 2012, in a single medical center. A study flow chart of this study
is displayed in in Fig 1. The study population was classified according to cause of VTE. Pro-
voked VTE was defined due to the following factors based on current guidelines: known overt
cancer, pregnancy including postpartum status, coagulopathy including thrombophilia, immo-
bilization, major surgery, and the use of oral or hormone replacement therapy. Unprovoked
VTE was defined as patients with VTE but in the absence of any cause. For the purpose of this
study, 169 patients comprised the analytic sample in this study. This study was approved by
the Institutional Review Board of Yonsei University, Severance Hospital, Seoul, Korea. Written
informed consent was exempt by the board as this study was retrospective in design. Patient
records/information was anonymized and de-identified prior to analysis.
Data examination
We retrospectively reviewed patients’medical records for information regarding age, sex, type
of VTE, and comorbidities. The prevalence of hypertension was defined as a history of being
diagnosed with hypertension, or use of antihypertensive medication. Prevalent diabetes melli-
tus was defined as having a history of being diagnosed with diabetes or the use of anti-glycemic
medication. Coronary artery disease was defined as a history of being diagnosed for coronary
artery disease. D-dimer was measured within 24 h of presenting to the medical department.
The level of D-dimer was quantitatively assessed by HemosIL D-dimer HS for ACL TOP
(Instrumentation Laboratory, Bedford, MA, USA), which is a latex-enhanced turbidimetric
immunoassay with an imprecision ranging between 2.3% and 6.6% and a detection limit of 21
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ng/ml. D-dimer was classified on the following D-dimer values:<2,000, 2,000–4,000, and
>4,000 ng/ml, and also logarithmically transformed (D-dimer + 1) as a continuous measure.
Study outcome
Patients were enrolled between January 2007 and October 2012, and followed through Febru-
ary 2015, until the last hospital visit from the first diagnosis date of VTE. During a median of
5.3 (interquartile range (IQR): 3.4–6.7) years study follow-up, patients were observed for an
endpoint of detecting occult cancer. The primary origin and metastatic state of occult cancer in
patients presenting with occult cancer was assessed. Data regarding the incidence of cancer
events during the study follow-up period were obtained by review of the medical records.
Statistical methods
Continuous variables are expressed as mean ± standard deviation (SD), and categorical vari-
ables are reported as counts with proportions. For the purpose of the study endpoint, our
Fig 1. Flow chart of the study cohorts.
doi:10.1371/journal.pone.0153514.g001
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sample was dichotomized according to those with detected occult cancer (i.e., indicator = 1) or
those without (i.e., indicator = 0). Comparisons between patient groups were performed by use
of Student’s t-test for continuous variables and Pearson’s chi square test for categorical param-
eters. The incidence rate of occult cancer was calculated and compared according to D-dimer
categories, pre-specified age groups, gender, and type of VTE. Multivariable Cox regression
analysis reporting hazard ratios (HR) with 95% confidence intervals (CI) was employed to
examine the risk of occult cancer according to D-dimer categories, adjusting for age, gender,
and type of VTE. The diagnostic performance of D-dimer levels>4,000 for predicting occult
cancer were assessed by calculating sensitivity, specificity, negative predictive value (NPV), and
positive predictive value (PPV) metrics. A p-value<0.05 was considered statistically signifi-
cant. All statistical analyses were performed using STATA Version 13 (StataCorp LP, College
Station, TX, USA).
Results
Frequency and distribution of occult cancer in VTE patients
In Table 1, of the 169 VTE patients, 24 (14.2%) were subsequently diagnosed with occult can-
cer. The incidence of occult cancer per 100 person years was 3.1 (95% CI: 2.1–4.7). The median
duration for detection of cancer after diagnosis of VTE was 6.5 (IQR 2–14) days. Overall, 21
(88%) of these patients were diagnosed with cancer during initial hospitalization, with the
remaining 3 (12%) patients diagnosed with cancer following discharge after first admission.
The median duration to diagnosis for 3 patients who were diagnosed with cancer after being
discharged from hospital was 104 days. Of those detected with occult cancer, 16 (66.7%)
patients presented with a metastatic state at cancer diagnosis. Further details of these patients’
characteristics are outlined in S1 Table.
D-dimer for predicting occult cancer
Clinical characteristics of patients with unprovoked VTE according to the presence and
absence of occult cancer are shown in Table 2. No significant differences in age, sex,
Table 1. Characteristics of patients with VTE-related occult cancer.
Number (%)
No. diagnosed during 1st admission 21 (87.5)
Diagnosis duration, days, median [IQR] 6.5 [2–14]
Cancer origin
Stomach 5 (20.8)
Colon 4 (16.7)
Lung 4 (16.7)
Ovary 2 (8.3)
Biliary 2 (8.3)
Lymphoma 2 (8.3)
Thyroid 2 (8.3)
etca 3 (12.5)
Metastatic state at cancer diagnosis 16 (66.7)
VTE, venous thromboembolism; IQR, interquartile range; etc, et cetera
a1 patient each in sarcoma, thymoma, and unknown origin
doi:10.1371/journal.pone.0153514.t001
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comorbidities, or type of VTE were observed between groups. D-dimer and Log transformed D-
dimer were significantly higher in patients with occult cancer as compared with those without.
Fig 2 displays the incidence proportions of occult cancer, and metastatic state according to
D-dimer categories. The proportion of occult cancer appeared higher in patients with baseline
Table 2. Baseline characteristics between patients with and without occult cancer.
Without occult cancer (n = 145) With occult cancer (n = 24) P-value
Age, years (mean ± SD) 60.9 ± 15.7 55.7 ± 11.7 0.121
Male, n (%) 76 (52.4) 9 (37.5) 0.176
Hypertension, n (%) 63 (43.5) 6 (25.0) 0.089
Diabetes mellitus, n (%) 13 (9.0) 3 (12.5) 0.584
Known CAD, n (%) 9 (6.21) 0 (0) 0.210
Type of VTE 0.116
Pulmonary embolism, n (%) 54 (37.2) 13 (54.2)
Deep vein thrombosis, n (%) 91 (62.8) 11 (45.8)
D-dimer, ng/ml (mean ± SD) 2,834.7 ± 5,287.2 5,313.9 ± 5,533.2 0.036
Log D-dimer (mean ± SD) 3.2 ± 0.5 3.5 ± 0.5 0.009
SD, standard deviation; CAD, coronary artery disease; VTE, venous thromboembolism
doi:10.1371/journal.pone.0153514.t002
Fig 2. Incidence proportion of occult cancer and cancer with metastatic state according to quantitative level of D-dimer.
doi:10.1371/journal.pone.0153514.g002
D-Dimer and Occult Cancer in Venous Thromboembolism
PLOSONE | DOI:10.1371/journal.pone.0153514 April 13, 2016 5 / 10
D-dimer levels>4,000 (e.g., 32.0%) when compared with the lower D-dimer levels of<2,000
(e.g., 9.3%) and 2,000–4,000 (e.g., 13.8%). Likewise, metastatic state at the time of cancer diag-
nosis was more predominant in patients with D-dimer levels>4,000.
In Table 3, depending on patient subsets, the incidence of occult cancer appeared higher in
those<60 years of age, among women, for those with a pulmonary embolism, or when concen-
trations of D-dimer were>4000, as compared with their respective counterparts. Notably, the
diagnostic performance of D-dimer levers>4,000 when screening for occult cancer yielded a
sensitivity, specificity, PPV, and NPV of 33.3%, 88.3%, 32%, 88.9%, respectively.
In Cox regression models, log transformed D-dimer was significantly associated with occult
cancer, and a metastatic state of cancer (Table 4). Further, after adjusting for age, sex, and type
Table 3. Incidence of occult cancer according to patient risk factors.
Number of patients Occult cancer cases Incidence/100 person years
Age group
<60 74 17 (23.0) 5.7
60–70 35 4 (11.4) 2.2
>70 60 3 (5.0) 1.0
Gender
Male 85 9 (10.6) 2.1
Female 84 15 (17.9) 4.4
VTE type
DVT 102 11 (10.8) 2.4
PE 67 13 (19.4) 4.3
D-dimer group
<2000 86 8 (9.3) 1.8
2000–4000 58 8 (13.8) 3.3
>4000 25 8 (32.0) 9.1
VTE, venous thromboembolism; DVT, deep vein thrombosis; PE, pulmonary embolism
doi:10.1371/journal.pone.0153514.t003
Table 4. Cox regression for the likelihood of occult or metastatic cancer according to D-dimer.
Occult cancer Metastatic state of cancer
HR 95% CI P value HR 95% CI P value
Unadjusted
Log D-dimer 3.56 1.48–8.64 0.005 7.83 2.64–23.25 <0.001
D-dimer groups
<2000 1 (Reference) 1 (Reference)
2000–4000 1.58 0.59–4.22 0.357 3.17 0.79–12.66 0.103
>4000 4.02 1.51–10.71 0.005 9.33 2.41–36.15 0.001
Adjusteda
Log D-dimer 3.98 1.58–10.02 0.003 10.06 3.08–32.87 <0.001
D-dimer groups
<2000 1 (Reference) 1 (Reference)
2000–4000 1.67 0.62–4.50 0.307 3.52 0.87–14.21 0.077
>4000 4.12 1.54–11.04 0.005 9.55 2.46–37.17 0.001
HR, hazard ratio; CI, conﬁdential interval
aAdjusted for age, gender, and type of venous thromboembolism
doi:10.1371/journal.pone.0153514.t004
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of DVT, the risk of occult as well as metastatic state of cancer for patients with a D-dimer con-
centration>4,000 increased by more than 4-fold (HR: 4.12, 95% CI: 1.54–11.04, P-
value = 0.005) and 9-fold (HR: 9.55, 95% CI: 2.46–37.17, P-value = 0.001), respectively, when
compared with those with a D-dimer level<2,000.
Discussion
In this retrospective observational study, we evaluated the predictive value of D-dimer for
occult cancer in patients with unprovoked VTE. Our results indicated that increasing D-dimer
levels were independently associated with a higher burden of occult cancer. Notably, a high D-
dimer level was found to be a robust predictor of occult cancer in patients with unprovoked
VTE.
Risk of cancer in patients with VTE
The relationship between VTE and occult cancer has long been recognized. Although cancer
most commonly provokes VTE, reciprocally, VTE may also lead to the diagnosis of occult can-
cer. Several epidemiological studies show that the risk of cancer is substantially elevated after
diagnosis of VTE. One study evaluated the risk of cancer after diagnosis of DVT and PE using
a population-based sample of 26,653 subjects, and demonstrated the risk of cancer was height-
ened during the first 6 months of follow-up [4]. Particularly, unprovoked VTE demonstrates a
higher incidence of occult cancer compared with provoked VTE. The annual risk for new can-
cers was more than 2-fold higher in patients presenting with unprovoked compared with those
with provoked VTE [5]. In a meta-analysis of 36 studies, the prevalence of diagnosed cancer
with unprovoked VTE was 10.0% from baseline to 12 months [6], which is fitting with the cur-
rent study results, whereby the proportion of diagnosed cancer in patients with unprovoked
VTE was 14.2%.
D-dimer and occult cancer
To date, studies evaluating the associations between D-dimer and occult cancer in patients
with unprovoked VTE are sparse. Of few existing, Rege et al. reported that a low D-dimer level
(i.e.,<1,000 ng/ml) is a strong negative predictor for malignancy [13]. Although the latter
study showed a significant association between D-dimer and malignancy in patients with VTE,
those results did not comprehensively evaluate the association of D-dimer and occult cancer
detected after diagnosis of VTE. In addition, Schutgens et al. also assessed the value of D-dimer
in predicting cancer in patients with DVT [14]. In that study, higher D-dimer levels during the
first few days of hospitalization were a strong indicator of an increased probability of occult
forms of cancer. Our findings support as well as extend prior studies that investigated the rela-
tionship between D-dimer and occult cancer in patients with VTE. Our study was focused pri-
marily on unprovoked VTE that had demonstrated a higher incidence of occult cancer
compared with provoked VTE caused by other risk factors. Our study findings underline the
possible association between high levels of baseline D-dimer and risk of occult cancer in
patients with unprovoked VTE.
Screening strategy for occult cancer in unprovoked VTE
Screening strategies for occult cancer in unprovoked VTE is an urgent issue that should be
addressed in the clinical setting. In a previous study regarding screening for cancer in patients
with unprovoked VTE, the findings were conflicting. Van Doormaal et al. proposed basic
screening such as careful history and physical examination is the most optimal strategy
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screening method for occult cancer in these patients [15]. More recently, multicenter, random-
ized, controlled trial encompassing 854 patients showed that extended cancer screening within
the abdomen and pelvis from CT did not provide a clinically significant benefit because of a
low prevalence of occult cancer [16]. Current guidelines also suggest that the search for occult
cancer following an episode of VTE might be confined to patients’ history, physical examina-
tion, basic laboratory tests, and chest X-ray [3]. By contrast, Piccioli et al. reported that exten-
sive screening for occult cancer in patients with unprovoked VTE is warranted because early
detection is likely to be associated with improved prognosis [17]. Taken together with the cur-
rent diagnostic findings, high D-dimer should perhaps be considered during screening for
occult cancer in these patient groups. Indeed, extensive screening for occult cancer may benefit
those who present with higher D-dimer levels. Though, clearly, further studies are needed to
assess the effectiveness for extensive screening of occult cancer in patients with unprovoked
VTE on the background of high D-dimer levels.
Limitations
The present study has some limitations that should be noted. The present study was retrospec-
tive and observational in nature. Therefore, the possibility of bias due to unmeasured con-
founding factors cannot be excluded. In addition, although we assessed some predictors of
cancer risk (e.g., age, gender, and VTE), the retrospective nature of this study made it challeng-
ing to obtain information regarding other important potential risk factors for cancer (i.e.,
smoking), which should be considered in forthcoming investigations. This study was a single-
center design and subjects comprised of Korean-Asian ethnicity only, which may have inferred
a selection bias. Therefore, these findings may not be extrapolated to other ethnic origins, or
specific Asian populations. Incidence of occult cancer was determined by review of medical
records only, which might infer a potential possibility of missing patients with diagnosed can-
cer. Although we reviewed 824 patients diagnosed with VTE, only 169 patients were included
as the analytic sample with 24 patients detected for having occult cancer. Particularly, the
results of this study showed an inverse relationship between increasing age and incidence of
occult cancer. This somewhat unusual association may be a consequence of a selection bias due
to the relatively small sample size–though there may also have been the possibility of survivor-
ship bias, possibly leading to an underestimation of a risk factor’s effect on disease risk [18].
Hence, our findings should be interpreted with caution, in light of the relatively low numbers
of events, which likely explain the wide CIs observed. Information regarding other diagnostic
tools for detecting occult malignancy was unavailable. Consequently, a reliable screening of
occult malignancy in patients with unprovoked VTE was beyond the scope of this study, and
could not be readily assessed.
Conclusions
In conclusion, the current study demonstrated that higher D-dimer levels represent a strong
independent indicator of increased risk of occult forms of malignancy in patients with unpro-
voked VTE. D-dimer levels may prove useful for augmenting cancer-screening strategies in
patients with unprovoked VTE. Though additional studies are needed to support this
contention.
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